Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: A double blind, randomised, placebo controlled multicentre study

Gut

Volumn 39, Issue 2, 1996, Pages 319-324

  Gyr, K ^a,b   Meier, R ^d   Haussler J ^e   Bouletreau P ^f   Fleig, W E ^g   Gatta, A ^h   Holstege, A ⁱ   Pomier Layrargues, G ^j   Schalm, S W ^k   Groeneweg, M ^k   Scollo Lavizzari, G ^c   Ventura, E ^l   Zeneroli, M L ^l   Williams, Roger ^m   Yoo, Y ⁿ   Amrein, R ^e  

^a KANTONSSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Kantonsspital Liestal   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e HÔTEL DIEU   (France)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g UNIVERSITY OF PADOVA   (Italy)

^h Klin und Poliklin F Inn Med I   (Germany)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^l KING S COLLEGE HOSPITAL   (United Kingdom)

^m Hallym University   (South Korea)

ⁿ NONE

more..

Author keywords

Benzodiazepines; Flumazenil; Liver disease; Portal systemic encephalopathy; PSE

Indexed keywords

BENZODIAZEPINE RECEPTOR; FLUMAZENIL;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9444274028     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.2.319     Document Type: Article

References (20)

1. Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev 1991; 43: 27-71.
2. Conn HO, Lieberthal M. The hepatic coma syndromes and lactulose. Baltimore: Williams and Wilkins, 1979: 6.
3. Jones EA, Gammal SA. Hepatic encephalopathy. In: Arias IM, Jakoby WB, Popper H, et al, eds. The liver: biology and pathobiology. 2nd ed. New York: Raven Press, 1988.
4. Basset ML, Mullen KD, Skolnik P, Jones EA. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABA benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 1987; 93: 1069-77.
5. Haefely W. The preclinical pharmacology of flumazenil. Eur J Anaesthesiol 1988; 5 (suppl 2): 25-36.
6. Amrein R, Hetzel W, Hartmann D, Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesthesiol 1988; 5 (suppl 2): 65-80.
7. Bansky G, Meier PJ, Ziegler WH, Walser H, Schmid M, Huber M. Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788). Lancet 1985; i: 1324-5.
8. Bansky G, Meier PJ, Riederer E, Walser H, Ziegler WH, Schmid M. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989; 97: 744-50.
9. Grimm G, Ferenci P, Katzenschlager R, Madl C, Schneeweiss B, Laggner AN, et al. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988; ii: 1392-4.
10. Meier R, Gyr K. Treatment of hepatic encephalopathy with the benzodiazepine antagonist flumazenil: a pilot study. Eur J Anaesthesiol 1988; 5 (suppl 2): 139-46.
11. Frenkel AL, Hermant JL, Blaise M, Levacher S, Volter F. Effect of flumazenil in hepatic encephalopathy in the alcoholic. Electroencephalography and clinical neurophysiology. Electroencephalogr Clin Neurophysiol 1992; 82: 95P.
12. Cadranel JF, El Younsi M, Pidoux B, Zylberberg P, Behnhamon Y, Valla D, et al. Immediate improvement of hepatic encephalopathy (portal systemic encephalopathy) in cirrhotic patients by flumazenil. Results of a double-blind cross-over study. European Journal of Gastroenterology and Hepatology 1995; 7: 325-9.
13. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology 1994; 19: 32-7.
14. Mullen KD, Szauter KM, Kaminsky-Russ K. Endogenous benzodiazepine activity in physiological fluids of patients with hepatic encephalopathy. Lancet 1990; ii: 81-3.
15. Van der Rijt CCD, Schalm SW, Meulstree J, Stignen TH. Flumazenil therapy for hepatic encephalopathy, a double-blind cross-over study. [Abstract]. Hepatology 1989; 10 (suppl): S90.
16. Kennedy J, Parbhoo SP, MacGillivray B, Sherlock S. Effect of extracorporeal liver perfusion on the electroencephalogram of patients in coma due to acute liver failure. Q J Med 1973; 42: 549-61.
17. Van der Rijt CD, Schalm SW, De Groot GH, De Vlieger M. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol 1984; 57: 423-6.
18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
19. Hettmansperger TP. Statistical inference based on ranks. New York: John Wiley, 1984: 133-40.
20. Basile AS, Harrison PM, Hughes RD, Gu Zi-Quang, Pannell L, McKinney A, et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994; 19: 112-21.